Next Article in Journal
Strategies to Make Telemedicine a Friend, Not a Foe, in the Provision of Accessible and Equitable Cancer Care
Previous Article in Journal
Symptom Clusters in Survivorship and Their Impact on Ability to Work among Cancer Survivors
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 15
Issue 21
10.3390/cancers15215120
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Cancers 2023, 15(12), 3185.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Ding et al. MBD3 as a Potential Biomarker for Colon Cancer: Implications for Epithelial–Mesenchymal Transition (EMT) Pathways. Cancers 2023, 15, 3185

by
Yuntao Ding
1,†,
Huizhi Wang
1,†,
Junqiang Liu
1,
Han Jiang
1,
Aihua Gong
2,* and
Min Xu
1,*
1
Department of Gastroenterology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang 212000, China
2
Hematological Disease Institute of Jiangsu University, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang 212001, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cancers 2023, 15(21), 5120; https://doi.org/10.3390/cancers15215120
Submission received: 6 September 2023 / Accepted: 9 October 2023 / Published: 24 October 2023
(This article belongs to the Section Cancer Biomarkers)
Versions Notes
In the published paper [1], there was an error regarding the affiliation for Huizhi Wang. Yuntao Ding and Huizhi Wang contributed equally to this work and share co-first authorship, as stated in the Author Contributions section. The updated affiliation should include: †—These authors contributed equally to this work. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Ding, Y.; Wang, H.; Liu, J.; Jiang, H.; Gong, A.; Xu, M. MBD3 as a Potential Biomarker for Colon Cancer: Implications for Epithelial-Mesenchymal Transition (EMT) Pathways. Cancers 2023, 15, 3185. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Ding, Y.; Wang, H.; Liu, J.; Jiang, H.; Gong, A.; Xu, M. Correction: Ding et al. MBD3 as a Potential Biomarker for Colon Cancer: Implications for Epithelial–Mesenchymal Transition (EMT) Pathways. Cancers 2023, 15, 3185. Cancers 2023, 15, 5120. https://doi.org/10.3390/cancers15215120

AMA Style

Ding Y, Wang H, Liu J, Jiang H, Gong A, Xu M. Correction: Ding et al. MBD3 as a Potential Biomarker for Colon Cancer: Implications for Epithelial–Mesenchymal Transition (EMT) Pathways. Cancers 2023, 15, 3185. Cancers. 2023; 15(21):5120. https://doi.org/10.3390/cancers15215120

Chicago/Turabian Style

Ding, Yuntao, Huizhi Wang, Junqiang Liu, Han Jiang, Aihua Gong, and Min Xu. 2023. "Correction: Ding et al. MBD3 as a Potential Biomarker for Colon Cancer: Implications for Epithelial–Mesenchymal Transition (EMT) Pathways. Cancers 2023, 15, 3185" Cancers 15, no. 21: 5120. https://doi.org/10.3390/cancers15215120

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop